Jeffrey Johnston, PhD

Education

• 2002, PhD, The Ohio State University, Pharmaceutics
• 1993, BS, The Ohio State University, Microbiology

Publications

• Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Sep;54(9):1996-2002. doi: 10.3109/10428194.2012.760733. Epub 2013 Jan 24. PMID: 23256542; PMCID: PMC3860322.
• Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet. 2013 Aug;52(8):705-12. doi: 10.1007/s40262-013-0064-7. PMID: 23588536; PMCID: PMC3720841.
• Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14. PMID: 24048792; PMCID: PMC3116936.
• Knoell DL, Johnston JS, Bao S, Kelley KA. A genotyping exercise for pharmacogenetics in pharmacy practice. Am J Pharm Educ. 2009 May 27;73(3):43. doi: 10.5688/aj730343. PMID: 19564986; PMCID: PMC2703267.
• Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009 Jan-Feb;1(1):31-40. doi: 10.4161/mabs.1.1.7472. PMID: 20046572; PMCID: PMC2715189.
• Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 1;871(1):15-21. doi: 10.1016/j.jchromb.2008.06.029. Epub 2008 Jun 26. PMID: 18635408; PMCID: PMC3782378.
• Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 1;868(1-2):110-5. doi: 10.1016/j.jchromb.2008.04.023. Epub 2008 Apr 22. PMID: 18490204; PMCID: PMC2504738.
• Gao W, Johnston JS, Miller DD, Dalton JT. Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino- phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab Dispos. 2006 Feb;34(2):254-60. doi: 10.1124/dmd.105.007120. Epub 2005 Nov 4. PMID: 16272403; PMCID: PMC2039883.
• Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL. Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res. 2003 Jul;20(7):957-61. doi: 10.1023/a:1024431218327. PMID: 12880279.